Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older;~* biopsy proven poorly differentiated carcinoma or adenocarcinoma of the rectum;~* lesions located within 12 cm of the anal verge (from colonoscopy assessment);~* ability to tolerate oral treatment;~* locally advanced tumor, classified by the presence of positive regional lymph nodes or primary tumor invasion beyond the serosa (T3 or T4), assessed by MRI;~* eligibility for curative surgery (no distant metastasis or invasion of bony structures of the pelvis);~* Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) 0-2;~* adequate hematologic functions (hemoglobin ≥ 10 g / dL \[5.6 mmol / L\]; neutrophil count ≥ 1,500 / mm3 and platelet count ≥ 100,000 / mm3), adequate renal function (serum creatinine less than 1.5 times the UNL) and adequate hepatic function (bilirubin less than 1.5 times the UNL; aspartate aminotransferase and alanine aminotransferase less than 2.5 times the UNL);~Exclusion Criteria:~* known hypersensitivity to metformin or its excipients;~* squamous carcinomas of the rectum or anal canal;~* chronic treatment with corticosteroids or other immunosuppressive agents;~* treatment with oral antidiabetic products;~* distant metastasis at diagnosis or tumor invasion of pelvic bone structures that may proscribe curative intent surgery;~* chronic or acute infections;~* use of drugs under study up to four weeks prior to randomization;~* pregnant or nursing patients;~* prior radiotherapy to the pelvic region;~* myocardial infarction up to six months prior to randomization, or uncontrolled ischemic heart disease;~* congestive heart insufficiency New York Heart Association (NYHA) III-IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant capecitabine and metformin (Type: EXPERIMENTAL): * Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Metformin 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions
- Neoadjuvant capecitabine and placebo (Type: PLACEBO_COMPARATOR): * Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Placebo 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions

Based on this trial design, predict the completion outcome and termination type (if applicable).